A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer by Huober, Jens et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
A multicentric observational trial of pegylated liposomal 
doxorubicin for metastatic breast cancer
Jens Huober*1, Werner Fett2, Arnd Nusch3, Michael Neise4, Marcus Schmidt5, 
Arthur Wischnik6, Steffen Gerhardt7, Thomas Goehler8, Hans-Joachim Lück9 
and Andreas Rost10
Address: 1Breast Center Kantonsspital, St Gallen, Switzerland, 2Oncological Practice, Wuppertal, Germany, 3Oncological Practice, Velbert, 
Germany, 4Oncological Practice, Krefeld, Germany, 5University of Mainz, Dept of Gynecology, Mainz, Germany, 6Clinical Center Augsburg, 
Augsburg, Germany, 7Oncological Practice, Gera, Germany, 8Oncological Practice, Dresden, Germany, 9Hannover Medical School, Hannover, 
Germany and 10Clinical Center Darmstadt, Darmstadt, Germany
Email: Jens Huober* - jens.huober@kssg.ch; Werner Fett - fett-onkologe@t-online.de; Arnd Nusch - nusch@aol.com; 
Michael Neise - praxis@onkologie-krefeld.de; Marcus Schmidt - Marcus.Schmidt@frauen.klinik.uni-mainz.de; 
Arthur Wischnik - wischnik@klinikum-augsburg.de; Steffen Gerhardt - drgerhardt@iogp-gera.de; Thomas Goehler - goehler@onkozentrum.de; 
Hans-Joachim Lück - hjlueck@arcor.de; Andreas Rost - onkologie@klinikum-darmstadt.de
* Corresponding author    
Abstract
Background: Pegylated liposomal doxorubicin (PLD) is active in metastatic breast cancer. This
observational study evaluated the efficacy and safety of PLD in patients treated during routine
clinical practice.
Methods: Eligible patients had metastatic breast cancer and were treated with PLD according to
the dose and schedule determined by their physician as part of routine practice. The primary
objectives were to analyze the efficacy and toxicity of PLD therapy.
Results: 125 patients were assessable. Median age was 62 years, 78% had performance status 0-1,
and 60% had estrogen-receptor-positive disease. PLD treatment was second- or third-line in 69%
of patients. Prior anthracyclines (adjuvant or metastatic) had been used in 56% of patients. The
majority of patients (79%) received PLD every 4 weeks at a median dose of 40 mg/m2. Overall
response rate was 43% in all patients and 34% in those previously treated with anthracyclines. The
most common grade 3/4 adverse events were skin toxicity/hand-foot syndrome (6%), and
leukopenia (3%).
Conclusions: This observational study supports the activity and tolerability of PLD in metastatic
breast cancer as demonstrated in PLD clinical trials.
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Background
Anthracyclines are highly active as single agents in the
treatment of metastatic breast cancer; however, their use is
limited by acute toxicities and the potential for cumula-
tive cardiac damage. The concern for cardiotoxicity is
heightened in patients who have already received an
anthracycline in the adjuvant setting [1].
The development of liposomal anthracyclines has
resulted in an improved safety profile and comparable
efficacy to conventional anthracyclines. In a phase III trial
comparing pegylated liposomal doxorubicin (PLD) to
conventional doxorubicin as first-line treatment for meta-
static breast cancer (MBC), no significant difference
occurred between arms in progression-free or overall sur-
vival [2]. However, cardiotoxicity was significantly
reduced with PLD, along with alopecia, nausea/vomiting,
and neutropenia. Hand-foot syndrome (HFS), stomatitis,
and mucositis were increased with PLD. Clinical trials sug-
gest these toxicities are dose-dependent [3,4].
Additional clinical trials have demonstrated the activity of
PLD in patients previously treated with anthracyclines as
well as taxane-refractory patients [5,6]. PLD is also an
effective, well tolerated treatment option in elderly
patients with MBC [7-9].
Due to strict eligibility requirements for enrollment,
results of clinical trials are often difficult to apply to
patients in everyday clinical practice. This is especially true
after regulatory approval, where the doses of new oncol-
ogy drugs used in daily practice often differ from the doses
recommended in their prescribing information [10]. An
observational study provides a useful tool for describing
everyday clinical practice since in these trials the safety
and efficacy of a drug in a non-selected group of patients
from community practice is reported, providing evidence
to support clinical trial findings. The purpose of this
observational study was to determine the activity and
safety of PLD as applied in routine clinical practice in Ger-
many. Further, the applied dose and treatment schedule
of PLD compared to a preselected study population was
investigated.
Methods
Patients were selected from medical practices and hospi-
tals in 34 German cities between July, 2003 and Decem-
ber, 2005 for this open-label, non-randomized, multi-
center observational study. Eligible patients were those
who had histologically confirmed metastatic breast can-
cer, and for whom the decision to treat with PLD had
already been made by their treating physician based on
routine clinical practice as described in national and inter-
national guidelines for the treatment of MBC [11,12]. No
other inclusion or exclusion criteria were applied. Due to
the observational character of this study, ethical approval
was not required according to the German medicines law
(Arneimittelgesetz, AMG) at the time of the trial. The
study was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice Guidelines.
Treatment
While the recommended dose of PLD in the prescribing
information, is 50 mg/m2 administered as a 30-60 minute
intravenous infusion on day 1, repeated every 28 days,
most practitioners use a PLD dose of 40 mg/m2 [13]. A
maximum of 12 cycles of PLD could be documented per
patient. All aspects of treatment (eg, dose, schedule)
remained at the discretion of the treating physician. How-
ever, physicians were to follow the contraindications,
warnings, and precautions as stated in the product infor-
mation for PLD. Treatment compliance was assessed by
analyzing the documented data on dose and schedule of
PLD administration. Except for progressive disease or
unacceptable toxicity, no criteria were set for removal of
patients from treatment or study; this decision was left to
the physician's discretion. Patient characteristics, support-
ive therapy, preceding treatments, dose changes, and
delays were documented.
Response and Toxicity Assessment
The primary objectives were to analyze the efficacy and
toxicity of PLD therapy in this unselected population. Sec-
ondary study objectives included the dose, number of
cycles, and treatment schedule of PLD administered,
Efficacy, defined as complete remission, partial remission,
stable disease, or disease progression, was assessed by the
evaluation of clinical response parameters according to
best clinical practice [14]. Response was evaluated as "best
response to therapy" once per patient. Occurrence of pro-
gressive disease was also documented. Median time of
progression-free and overall survival were estimated by
Kaplan-Meier analysis. Toxicities were classified according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE) in the version 2.0 of
1994. Adverse events were recorded at the end of every
cycle.
Statistical Analysis
Data from patients who received at least one cycle of PLD
and whose documentations were completed were ana-
lyzed for toxicity and efficacy. Descriptive and explorative
statistical analysis was performed for patient baseline
data, therapy data, and response data. Kaplan-Meier anal-
ysis was used to evaluate progression-free and overall sur-
vival.
Results
Data from 132 women were evaluated for inclusion in the
analysis. Of these, 125 patients who received at least one
cycle of PLD and whose documentations were completed,BMC Cancer 2010, 10:2 http://www.biomedcentral.com/1471-2407/10/2
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checked and signed by the physician were assessable for
analysis of efficacy and toxicity. Patient demographics and
tumor characteristics are detailed in Table 1. The majority
(n = 123) of patients had received prior hormonal therapy
or chemotherapy. PLD was administered as first-line ther-
apy in 14 patients (11%) and as second- or third-line ther-
apy in 86 patients (69%). Over half (n = 70; 56%) had
received prior anthracycline-based chemotherapy either
in the adjuvant or metastatic setting.
For all patients, 649 cycles of PLD were recorded with a
median of 4 cycles per patient (range, 1 to 12). The most
common duration of therapy was 4 courses received by 27
patients (21%), followed by 6 courses (25 patients, 20%)
and 3 courses (24 patients, 19%). The maximum number
of 12 cycles was reported for 7% of patients.
Treatment intervals were at the physician's discretion.
Schedules of every 2, 3, 4, or 5 weeks were reported, with
the median PLD dose dependent on the schedule. Patients
generally received approximately 10 mg/m2  per week
(Table 2). Administration every 4 weeks was the most fre-
quently-used interval, applied in 79% of the patients.
Dose reductions occurred in 27 patients (22%), and 38 of
the 649 courses (6%); non-hematologic toxicities were
the most frequent cause. Dose delays occurred in 37
patients (30%), which was 47 (7%) of courses. Patient
wish was the most frequently cited reason for treatment
delay (19 of the 47 courses). Toxicity, either hematologic
or non-hematologic, led to delay in less than 2% of treat-
ment courses. Because a maximal number of courses was
not defined, discontinuation of therapy was left to the
physician's discretion and could include more than one
reason. The primary reasons for treatment discontinua-
tion included progressive disease (39% of patients) and
end of regular therapy (36% of patients).
Efficacy
Response rates in all patients and in those with prior
anthracycline exposure are detailed in Table 3. The overall
response rate was 42.4% in all patients and 34.3% in
those previously treated with anthracyclines. Considering
stable disease, a benefit was seen in 72% of all patients
and in 70% in those previously treated with anthracy-
clines. When broken down by line of treatment, response
rates for patients in the first- and second-line treatment
setting was 47.8%; patients with > 2 lines of treatment had
a response rate of 36.2% (Table 3).
Kaplan-Meier estimates of progression-free and overall
survival in the overall population are shown in Figure 1A.
The median progression-free survival time was 7.2
months (95% CI: 5.4-8.6), and the median overall sur-
Table 1: Patient Demographics and Tumor Characteristics
Characteristic No. Patients (%)
N = 125
Median age, years (range) 62 (37-84)
Performance status (ECOG)
0-1 98 (78)
22 1  ( 1 7 )
33  ( 2 )
Unknown 3 (2)
Hormone receptor status
Positive 75 (60)
Negative 37 (30)
Unknown 13 (10)
Active Treatment setting
Neoadjuvant 1 (<1)
Adjuvant 1 (<1)
First-line advanced 14 (11)
Second-line advanced 51 (41)
Third-line advanced 35 (28)
Fourth-line advanced or greater 23 (18)
Prior treatments
Surgery 116 (93)
Hormone therapy 89 (71)
Prior anthracycline therapy 70 (56)
Palliative chemotherapy 81 (65)
Adjuvant chemotherapy 54 (43)
Immunotherapy 8 (6)
Site of metastasis N = 123
Bone 69 (56)
Liver 56 (4)
Lung 44 (36)
Skin 14 (11)
Lymph nodes 13 (11)
Pleura 8 (6)
Brain 7 (6)
Others 26 (21)
Table 2: Treatment Schedule and Dose
Treatment Interval (Cycle Length) No. Patients (%)
N = 120*
Median PLD Dose (mg/m2)P L D  D o s e
Range (mg/m2)
2 weeks 7 (6) 20 15-20
3 weeks 8 (7) 32 27-40
4 weeks 95 (79) 40 20-50
5 weeks 10 (8) 40 30-50
* Five patients had only one documented cycle of PLD and therefore treatment interval could not be analyzed.BMC Cancer 2010, 10:2 http://www.biomedcentral.com/1471-2407/10/2
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vival time was 20.8 months (95% CI: 15.4-22.6). In the
70 patients pretreated with anthracycline chemotherapy,
the median progression-free survival time was 5.5 months
(95% CI: 3.8-8.6), and the median overall survival time
was 15.4 months (95% CI: 12.5-21.9; Figure 1B).
Safety
No unexpected toxicities occurred. The most common
adverse events of all grades were anemia, leukopenia, alo-
pecia, skin toxicity, pain, stomatitis, and nausea (Table 4).
The most frequent grade 3 or 4 adverse events were skin
toxicity/hand-foot syndrome (6%), and leukopenia (3%).
Grade 2 skin toxicity/hand-foot syndrome, which can also
be bothersome, was seen in 14% of patients. Five cardiac
adverse events were reported in 4 patients, in all but 1
recorded as grade 1 or 2 in severity: cardiac arrhythmia
and heart palpitation (in the same patient), heart palpita-
tion, left ventricular systolic dysfunction (in one patient
grade 3). Death was documented for 9 patients. In one
case, the death was recorded as possibly related to PLD
treatment. Of the remaining 8 deaths, 6 were considered
by the physician to be not related to treatment (due to
progressive disease) and 2 occurred greater than 3 months
after the last PLD cycle and were therefore not reported as
adverse events.
Discussion
From this observational study, practice patterns surround-
ing the use of PLD as well as the activity and safety of PLD
as applied in routine clinical practice for patients with
metastatic breast cancer can be characterized. The major-
ity of patients received PLD as second- or third-line ther-
apy; only 11% received this agent as first-line treatment.
While a variety of dosing schedules were employed, nearly
80% received their PLD dose every 4 weeks (usually 40
mg/m2) and about two-thirds of these received 4 to 6
cycles. While the recommended dose of PLD in the pre-
scribing information is 50 mg/m2 repeated every 28 days,
most practitioners use a PLD dose of 40 mg/m2 through-
out palliative settings most likely because of higher toler-
ability [3,15]. Thus PLD doses of 50 mg/m2 every 28 days
as usually administered in clinical trials is not widely used
in routine clinical practice.
The activity of PLD in metastatic breast cancer in different
treatment lines as monotherapy or in combination ther-
apy has been demonstrated in multiple phase II and III
studies [2,5,6,8,16,17]. In a randomized phase III trial,
PLD was demonstrated to be equally effective to conven-
tional doxorubicin as first-line treatment of women with
MBC [2]. The primary advantage of PLD in this and other
studies was its favorable toxicity pattern, with low hema-
tologic toxicity, a low rate of alopecia, less nausea and
vomiting, and a diminished risk of cardiotoxicity when
compared to conventional doxorubicin.
Though a limitation of this study is its observational
nature with heterogeneous treatment schemes and differ-
ent nonuniform toxicity management practices, the study
supports the activity, tolerability and safety of PLD in an
unselected population treated in routine clinical practice.
In this study, no specifications with respect to tumor
measurement or response confirmation were made as
would be present in the conduct of a clinical trial. There-
fore, limited comparisons can be made with published
clinical trials. The majority of patients in this study (87%)
received PLD as second-line or later therapy. Complete or
partial response was documented in 53 patients (42.4%),
with a clinical benefit rate of 72%. Response rates
observed in published clinical trials of PLD in previously-
treated patients with metastatic breast cancer (second-line
or higher) have ranged from 10% to 31% [5,6,16]. The
higher response rates in our study could be due to the
response criteria not being as strict as those in a clinical
trial. Furthermore, it is not uncommon for response rates
to be lower when assessed by independent review as com-
pared to investigator assessment. Nevertheless, a clinical
benefit with PLD was apparent in this study.
The mostly used dose of PLD in this observational study
was 40 mg/m2. Even though no direct comparisons
between a PLD dose of 40 mg/m2 and 50 mg/m2 exist,
Table 3: Best Response to PLD Therapy
Best Response All Patients
N = 125
Patients with Prior Anthracycline Therapy N = 70 Response by Line of Treatment
1st/2nd Line ≥ 3rd Line
N = 65 N = 58
No. Patients (%)
Complete response 6 (4.8) 2 (2.9) 4 (6.2) 2 (3.4)
Partial response 47 (37.6) 22 (31.4) 27 (41.5) 19 (32.8)
Stable disease 37 (29.6) 25 (35.7) 15 (23.1) 22 (37.9)
Progressive disease 28 (22.4) 17 (24.3) 18 (27.7) 10 (17.2)
Not determined 7 (5.6) 4 (5.7) 1 (1.5) 5(8.6)BMC Cancer 2010, 10:2 http://www.biomedcentral.com/1471-2407/10/2
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Overall and Progression-Free Survival Figure 1
Overall and Progression-Free Survival. (A) Kaplan-Meier estimates of overall survival and progression-free survival in 
patients treated with PLD for metastatic breast cancer. (B) Kaplan-Meier estimates of overall survival and progression-free 
survival in anthracycline-pretreated patients treated with PLD for metastatic breast cancer.
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indirect comparisons suggest that 40 mg/m2 is equally
effective to 50 mg/m2 with distinctively lower side effects,
especially skin toxicity [3,18,19].
Several trials have demonstrated that PLD is active in
patients previously treated with anthracyclines, as well as
in patients progressing on anthracyclines, suggesting
incomplete cross-resistance between PLD and conven-
tional anthracyclines [5,6,20]. More than half of the
patients in our study (N = 70) had been previously treated
with an anthracycline, and attained a 34.3% response rate
and a 70% clinical benefit rate to PLD, corroborating as
well a benefit of PLD in an anthracycline pretreated
patient population.
Our investigation showed that PLD could be safely
administered in clinical practice, with a low rate of severe
toxicities. Specifically, grade 3 and 4 hematologic and gas-
trointestinal toxicities were very rare. Furthermore, com-
plete alopecia was only seen in very few patients (5%). In
the palliative setting with limited life expectancy, this is a
major advantage compared to doxorubicin. The most fre-
quent PLD-associated side effects in clinical practice, such
as skin toxicity/hand-foot syndrome and mucositis, were
similar to those reported in clinical trials. Of note, grade 3
and 4 events were only observed in 7% and 2% of
patients, respectively. In randomized phase III trials, the
incidence of grade 3/4 hand-foot syndrome has been
17%-19% [2,6]. The lower incidence of hand-foot-syn-
drome in our study may be due to the freedom physicians
had to administer lower doses of PLD and to use individ-
ual treatment schedules. Also, while randomized phase III
trials utilized a PLD dose of 50 mg/m2 every 4 weeks,
patients in this study received median PLD doses of 40
mg/m2 every 4 weeks so that patients generally received 10
mg/m2 PLD per week, a dose slightly lower than the rec-
ommended 12.5 mg/m2 per week (equivalent to 50 mg/
m2/4 weeks). Indeed, reductions in hand-foot syndrome
have been observed in phase II trials utilizing doses simi-
lar to what was used in this study. For example Coleman
et al observed a 2% rate of grade 3-4 hand-foot syndrome
events with a PLD dose of 60 mg/m2 every 6 weeks, and
Al-Batran et al observed no grade 3/4 HFS with a PLD dose
of 40 mg/m2 every 4 weeks (each dosing schedule equiva-
lent to approximately 10 mg/m2/week) [3,4]. Salzberg et
al observed grade 4 HFS only in patients treated with 50
mg/m2[21]. It should also be noted that the frequency of
examinations are not defined in an observational study;
therefore, patients may not be queried about adverse
events as frequently as would occur during the conduct of
an interventional clinical trial.
Conclusions
In conclusion, this observational study, evaluating the use
of PLD for the treatment of MBC in routine clinical prac-
tice, supports the activity and tolerability of PLD as dem-
onstrated in clinical trials. Even in heavily pretreated
patients PLD could be safely administered with low severe
hematologic and non-hematologic toxicity. The doses and
schedules utilized in clinical practice are slightly lower
than recommended in the prescribing information and
appear to be active while reducing the incidence of hand-
foot syndrome.
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